Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus

Overview

Journal ACG Case Rep J

Specialty Gastroenterology

Date 2021 Sep 22

PMID 34549064

Citations 1

Authors

Alyson Kaplan

Elliott DeHaan

Charles Maltz

Affiliations

Soon will be listed here.

Abstract

Despite the decreasing morbidity associated with the human immunodeficiency virus (HIV), a large percentage of persons with HIV have at least 1 drug resistance mutation. Ibalizumab, a recently approved drug, targets multidrug-resistant HIV. We present a case of reactivation of hepatitis B after initiation of ibalizumab therapy.

Citing Articles

Current drugs for HIV-1: from challenges to potential in HIV/AIDS.

Peng Y, Zong Y, Wang D, Chen J, Chen Z, Peng F Front Pharmacol. 2023; 14:1294966.

PMID: 37954841 PMC: 10637376. DOI: 10.3389/fphar.2023.1294966.

References

Kuritzkes D . HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS. 2009; 4(2):82-7. PMC: 2753507. DOI: 10.1097/COH.0b013e328322402e. View

Wensing A, Calvez V, Ceccherini-Silberstein F, Charpentier C, Gunthard H, Paredes R . 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019; 27(3):111-121. PMC: 6892618. View

Beccari M, Mogle B, Sidman E, Mastro K, Asiago-Reddy E, Kufel W . Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection. Antimicrob Agents Chemother. 2019; 63(6). PMC: 6535568. DOI: 10.1128/AAC.00110-19. View

Di Bisceglie A, Lok A, Martin P, Terrault N, Perrillo R, Hoofnagle J . Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?. Hepatology. 2014; 61(2):703-11. PMC: 5497492. DOI: 10.1002/hep.27609. View

Kao J, Chen P, Lai M, Chen D . Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. Hepatology. 2001; 34(4 Pt 1):817-23. DOI: 10.1053/jhep.2001.28188. View

Reimann K, Burkly L, Burrus B, Waite B, Lord C, Letvin N . In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AIDS Res Hum Retroviruses. 1993; 9(3):199-207. DOI: 10.1089/aid.1993.9.199. View

Law M, Ho R, Cheung C, Tam L, Ma K, So K . Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol. 2016; 22(28):6484-500. PMC: 4968128. DOI: 10.3748/wjg.v22.i28.6484. View

Toma J, Weinheimer S, Stawiski E, Whitcomb J, Lewis S, Petropoulos C . Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J Virol. 2011; 85(8):3872-80. PMC: 3126132. DOI: 10.1128/JVI.02237-10. View

Moore J, Sattentau Q, Klasse P, Burkly L . A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol. 1992; 66(8):4784-93. PMC: 241306. DOI: 10.1128/JVI.66.8.4784-4793.1992. View

10.

Iacob S, Iacob D . Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy. Front Microbiol. 2017; 8:2323. PMC: 5711820. DOI: 10.3389/fmicb.2017.02323. View

11.

Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata C . Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2000; 32(1):144-8. DOI: 10.1086/317535. View